Literature DB >> 3089553

Bone remodeling during the development of osteoporosis in paraplegia.

A Chantraine, B Nusgens, C M Lapiere.   

Abstract

Osteoporosis developing during the first weeks after the onset of traumatic paraplegia was studied with cortical and cancellous samples of iliac crest and tibia of 14 patients, and compared to normals. We used a procedure of bone particle fractionation (according to degree of mineralization) that allowed us to establish a profile reflecting the metabolic remodeling of bone and to analyze the organic matrix of the newly synthesized tissue. In paraplegics, we observed a large increase in the proportion of little calcified bone in the cortical as well as in the cancellous bone. Based on amino acid analyses, we found a decreased number of hydroxyproline residues in the newly synthesized organic matrix from paraplegia bone resulting either from an alteration of the prolyl hydroxylation or from the presence of an excess of noncollagen polypeptides. These results, together with previously published data reporting increased urinary hydroxyproline and calcium kinetic parameters, suggest an enhanced rate of skeletal remodeling in acute paraplegia. When investigated 2 years after injury, the patterns of distribution approach that of normal subjects.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3089553     DOI: 10.1007/bf02555744

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  13 in total

1.  Bone metabolism, parathyroid hormone, and calcitonin in paraplegia.

Authors:  A Chantraine; G Heynen; P Franchimont
Journal:  Calcif Tissue Int       Date:  1979-07-03       Impact factor: 4.333

2.  Longitudinal study of calcium and bone metabolism in paraplegic patients.

Authors:  P Bergmann; A Heilporn; A Schoutens; J Paternot; A Tricot
Journal:  Paraplegia       Date:  1977-08

3.  Physiological senile involution and pathological rarefaction of bone. Quantitative and comparative histological data.

Authors:  P Meunier; P Courpron; C Edouard; J Bernard; J Bringuier; G Vignon
Journal:  Clin Endocrinol Metab       Date:  1973-07

4.  Effect of prolonged bed rest on bone mineral.

Authors:  C L Donaldson; S B Hulley; J M Vogel; R S Hattner; J H Bayers; D E McMillan
Journal:  Metabolism       Date:  1970-12       Impact factor: 8.694

5.  The protein in the matrix of bone.

Authors:  B Nusgens; A Chantraine; C M Lapiere
Journal:  Clin Orthop Relat Res       Date:  1972       Impact factor: 4.176

6.  Clinical investigation of bone metabolism in spinal cord lesions.

Authors:  A Chantraine
Journal:  Paraplegia       Date:  1971-02

7.  Sequential studies of urinary hydroxyproline and serum alkaline phosphatase in acute paraplegia.

Authors:  L Klein; S Van Den Noort; J J DeJak
Journal:  Med Serv J Can       Date:  1966 Jul-Aug

8.  Intra-medullary pressure and intra-osseous phlebography in paraplegia.

Authors:  A Chantraine; C van Ouwenaller; H J Hachen; P Schinas
Journal:  Paraplegia       Date:  1979-11

9.  Bone loss in response to long-term immobilisation.

Authors:  H K Uhthoff; Z F Jaworski
Journal:  J Bone Joint Surg Br       Date:  1978-08

10.  Postmenopausal osteoporosis. A heterogeneous disorder as assessed by histomorphometric analysis of Iliac crest bone from untreated patients.

Authors:  M P Whyte; M A Bergfeld; W A Murphy; L V Avioli; S L Teitelbaum
Journal:  Am J Med       Date:  1982-02       Impact factor: 4.965

View more
  20 in total

1.  Assessment of anthropometric, systemic, and lifestyle factors influencing bone status in the legs of spinal cord injured individuals.

Authors:  P Eser; A Frotzler; Y Zehnder; H Schiessl; J Denoth
Journal:  Osteoporos Int       Date:  2004-05-11       Impact factor: 4.507

2.  Zoledronic acid administration failed to prevent bone loss at the knee in persons with acute spinal cord injury: an observational cohort study.

Authors:  William A Bauman; Christopher M Cirnigliaro; Michael F La Fountaine; LeighAnn Martinez; Steven C Kirshblum; Ann M Spungen
Journal:  J Bone Miner Metab       Date:  2014-08-27       Impact factor: 2.626

3.  Difference in intraosseous blood vessel volume and number in osteoporotic model mice induced by spinal cord injury and sciatic nerve resection.

Authors:  Wen-Ge Ding; Wei-hong Yan; Zhao-Xiang Wei; Jin-Bo Liu
Journal:  J Bone Miner Metab       Date:  2011-11-08       Impact factor: 2.626

4.  [Surgery for fractures of the lower extremities in cases of chronic spinal cord injury].

Authors:  C Bärlehner; V Böhm; R Flieger; T Meiners
Journal:  Orthopade       Date:  2005-02       Impact factor: 1.087

Review 5.  Heterogeneity of osteoporotic syndromes and the response to calcitonin therapy.

Authors:  L V Avioli
Journal:  Calcif Tissue Int       Date:  1991       Impact factor: 4.333

6.  Acute severe hypercalcemia after traumatic fractures and immobilization in hypophosphatasia complicated by chronic renal failure.

Authors:  Michael P Whyte; Rattana Leelawattana; William R Reinus; Chang Yang; Steven Mumm; Deborah V Novack
Journal:  J Clin Endocrinol Metab       Date:  2013-09-24       Impact factor: 5.958

Review 7.  Bone loss at the distal femur and proximal tibia in persons with spinal cord injury: imaging approaches, risk of fracture, and potential treatment options.

Authors:  C M Cirnigliaro; M J Myslinski; M F La Fountaine; S C Kirshblum; G F Forrest; W A Bauman
Journal:  Osteoporos Int       Date:  2016-12-05       Impact factor: 4.507

8.  Evaluation of bone mineral density in patients with spinal cord injury.

Authors:  Kurtulus Kaya; Canan Aybay; Sumru Ozel; Nilufer Kutay; Ordu Gokkaya
Journal:  J Spinal Cord Med       Date:  2006       Impact factor: 1.985

Review 9.  Osteoporosis after spinal cord injury.

Authors:  Sheng-Dan Jiang; Li-Yang Dai; Lei-Sheng Jiang
Journal:  Osteoporos Int       Date:  2005-10-11       Impact factor: 4.507

Review 10.  Exercise recommendations for individuals with spinal cord injury.

Authors:  Patrick L Jacobs; Mark S Nash
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.